– USA, MD – NexImmune, Inc. (Nasdaq: NEXI), a clinical-stage biotechnology company today announced the appointment of Kristi Jones to its Board of Directors as CEO, replacing Scott Carmer who submitted his resignation this week.
“The Board is pleased to appoint Kristi Jones as our new CEO and member of the Board of Directors. Kristi’s decades of experience in the biotechnology and pharmaceutical industries, which includes her playing a pivotal role in NexImmune’s strategic vision as CBO and, most recently, COO, make her the ideal candidate to lead the Company going forward. As we begin this transition, we are fortunate to have such a talented, innovative, and experienced leader to take us into the next phase of growth for the Company,” said Board Chairman, Sol Barer.
About Kristi Jones
Before her roles as CBO and COO at NexImmune, Kristi Jones spent more than 25 years in various strategic and operational leadership roles at AstraZeneca (and its biologics R&D subsidiary, MedImmune), Genentech, and Eli Lilly. At AstraZeneca, she was VP of Portfolio Strategy and Management, where she played an instrumental role in building a scientifically innovative, diverse portfolio creating new value for the Company. Before that role, she served as VP of Global Strategic Marketing to shape product plans and prepare MedImmune for multiple launches. Previously, Ms. Jones held multiple leadership roles with increasing responsibility at Genentech/Roche, where she worked for 16 years, including Head of Immunology and Ophthalmology in Global Portfolio and Product Strategy at Roche, Head of the Endocrine and Pulmonary franchise at Genentech, and Head of Immunology Business Unit Operations and Pipeline Planning at Genentech. Ms. Jones also served in a consulting role for various companies and organizations and serves on the Life Science Panel for Springboard Enterprises focused on start-up companies led by women. She is also an elected member of the Cell Therapy Committee of the Alliance for Regenerative Medicine.
“It has been my privilege to be a part of NexImmune’s leadership team for the past six years, and I am honored to take on these new responsibilities,” commented Kristi Jones. “I want to thank the Board of Directors for an extraordinary opportunity, and I look forward to building upon our groundbreaking efforts to unlock the potential of immunotherapies and revolutionize treatments for patients with high unmet medical need.”
Ms. Jones received her RPh from the University of Texas and a BS in Biology from Texas Tech University.
About NexImmune
NexImmune is a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to employ the body’s T cells to generate a specific, potent, and durable immune response. The backbone of NexImmune’s approach is a proprietary Artificial Immune Modulation nanoparticle technology platform. The AIM technology enables NexImmune to construct nanoparticles that function as synthetic dendritic cells capable of directing a specific T cell-mediated immune response. AIM constructed nanoparticles employ natural biology to engage, activate and expand endogenous T cells in ways that combine anti-tumor attributes of antigen-specific precision, potency, and long-term persistence with reduced potential for off-target toxicities.
NexImmune’s two lead programs, NEXI-001 and NEXI-002, are in Phase 1/2 clinical trials for the treatment of relapsed AML after allogeneic stem cell transplantation and multiple myeloma refractory to at least 3 prior lines of therapy, respectively. NexImmune is also developing new AIM nanoparticle constructs and modalities for potential clinical evaluation in oncology and disease areas outside of oncology, including autoimmune disorders and infectious disease.
For more information: https://www.neximmune.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
